Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use

Sleep

Volumn 37, Issue 3, 2014, Pages 489-496

  Vermeeren, Annemiek ^a   Vuurman, Eric F P M ^a   Leufkens, Tim R M ^a   Van Leeuwen, Cees J ^a   Van Oers, Anita C M ^a   Laska, Eugene ^b,c   Rico, Salvador ^d   Steinberg, Frank ^d   Roth, Thomas ^e  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Transcept Pharmaceuticals Inc   (United States)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

Driving; Hypnotics; Sex; Zolpidem sublingual; Zopiclone

Indexed keywords

PLACEBO; ZOLPIDEM; ZOPICLONE;

ADULT; ARTICLE; BEDTIME DOSAGE; CAR DRIVING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; SOMNOLENCE; STANDARD DEVIATION OF LATERAL POSITION SCORE; TRAFFIC; YOUNG ADULT;

DRIVING; HYPNOTICS; SEX; ZOLPIDEM SUBLINGUAL; ZOPICLONE;

ADMINISTRATION, SUBLINGUAL; ADULT; AUTOMOBILE DRIVING; AZABICYCLO COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MOTOR SKILLS; NETHERLANDS; PIPERAZINES; PYRIDINES; SEX CHARACTERISTICS; TIME FACTORS; YOUNG ADULT;

EID: 84896882346     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.3482     Document Type: Article

References (37)

1. Ohayon MM. Nocturnal awakenings and difficulty resuming sleep: their burden in the European general population. J Psychosom Res 2010;69:565-71.
2. Ohayon MM, Krystal A, Roehrs TA, Roth T, Vitiello MV. Using difficulty resuming sleep to define nocturnal awakenings. Sleep Med 2010;11:236-41.
3. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-328. (Pubitemid 38526714)
4. DuPont RL, Voas RB, Walsh JM, Shea C, Talpins SK, Neil MM. The need for drugged driving per se laws: a commentary. Traffic Inj Prev 2012;13:31-42.
5. Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and metaanalysis of epidemiological and experimental evidence. Drug Saf 2011;34:125-56.
6. Gustavsen I, Al-Sammurraie M, Mørland J, Bramness JG. Impairment related to blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers. Accid Anal Prev 2009;41:462-6.
7. Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009;18:387-96.
8. Leufkens TR, Ramaekers JG, de Weerd AW, Riedel WJ, Vermeeren A. Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study. Psychopharmacology (Berl) 2014 Jan 24. [Epub ahead of print].
9. Leufkens TR, Vermeeren A. Highway driving in elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin Psychopharmacol 2009;29:432-8.
10. Mets MA, de Vries JM, de Senerpont Domis LM, Volkerts ER, Olivier B, Verster JC. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011;34:1327-34.
11. Ramaekers JG, Conen S, de Kam PJ, et al. Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology Berl 2011;215:321-32.
12. Vermeeren A, Danjou PE, O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998;13(Suppl 2):S98-107.
13. Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A. Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep 2002;25:224-31. (Pubitemid 34193585)
14. Volkerts ER, O'Hanlon JF. Hypnotics' residual effects on driving performance. In: O'Hanlon JF, De Gier JJ, eds. Drugs and driving. Oxford: Taylor Francis, 1986:123-35.
15. Verster JC, Volkerts ER, Schreuder AH, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol 2002;22:576-83. (Pubitemid 35416783)
16. Perdue Pharma LP. Intermezzo - zolpidem tartrate tablet. Accessed August 27, 2013. Available from: http://app.purduepharma.com/xmlpublishing/pi.aspx?id= i.
17. Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB; Intermezzo Study Group. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 2008;31:1277-84.
18. Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep 2013;36:189-96.
19. Roth T, Mayleben D, Corser BC, Singh NN. Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. Hum Psychopharmacol 2008;23:13-20. (Pubitemid 351166064)
20. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61. (Pubitemid 28531600)
21. Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother 2012;13:879-93.
22. O'Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984;18:121S-29S. (Pubitemid 15184113)
23. Verster JC Roth T. Standard Operation Procedures for conducting the on-the-road driving test, and measurement of the Standard Deviation of Lateral Position (SDLP). Int J Gen Med 2011;4:359-71.
24. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995;50:234-42.
25. Vuurman EF, Muntjewerff ND, Uiterwijk MM, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996;50:475-82. (Pubitemid 26281067)
26. Brookhuis K. How to measure driving ability under the influence of alcohol and drugs, and why. Hum Psychopharmacol Clin Exp 1998;13:S64-9. (Pubitemid 28512910)
27. Laska E, Meisner M, Wanderling J. A maximally selected test of symmetry about zero. Stat Med 2012;31:3178-91.
28. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003;56:297-304. (Pubitemid 37069221)
29. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther 2000;293:435-43. (Pubitemid 30244092)
30. Louwerens JW, Gloerich ABM, De Vries G, Brookhuis KA, O'Hanlon JF. The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: International Congress on Alcohol, Drugs and Traffic Safety. Amsterdam: Exerpta Medica, 1987:183-6.
31. Vermeeren A, Vuurman E, Van Oers A, et al. Effects of suvorexant, an orexin receptor antagonist, on next day driving performance in healthy volunteers. Neuropsychopharmacology 2012;38:S320-1.
32. Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traf Inj Prev 2012;13:286-92.
33. Verster JC, Roth T. The prevalence and nature of stopped on-the-road driving tests and the relationship with objective performance impairment. Accid Anal Prev 2012;45:498-506.
34. Verster JC, Roth T. Predicting psychopharmacological drug effects on actual driving (SDLP) from psychometric tests measuring driving-related skills. Psychopharmacology 2012;220:293-301.
35. Borkenstein RF, Crowther RF, Shumate RP, Ziel WB, Zylman R. The role of the drinking driver in traffic accidents (The Grand Rapids Study). 2nd ed. Blutalkohol 1974;11:1-132.
36. Krüger HP, Vollrath M. The alcohol-related accident risk in Germany: procedure, methods and results. Accid Anal Prev 2004;36:125-33.
37. Verster JC, Spence DW, Shahid A, Pandi-Perumal SR, Roth T. Zopiclone as positive control in studies examining the residual effects of hypnotic drugs on driving ability. Curr Drug Saf 2011;6:209-18.